Currently, there are 309.77M common shares owned by the public and among those 129.91M shares have been available to trade.
The company’s stock has a 5-day price change of -1.53% and -16.43% over the past three months. AMRX shares are trading -2.40% year to date (YTD), with the 12-month market performance up to 38.04% higher. It has a 12-month low price of $5.01 and touched a high of $9.48 over the same period. AMRX has an average intraday trading volume of 1.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.47%, -4.63%, and -1.00% respectively.
Institutional ownership of Amneal Pharmaceuticals Inc (NASDAQ: AMRX) shares accounts for 36.66% of the company’s 309.77M shares outstanding.
It has a market capitalization of $2.40B and a beta (3y monthly) value of 1.06. The earnings-per-share (ttm) stands at -$0.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.84% over the week and 3.22% over the month.
Earnings per share for the fiscal year are expected to decrease by -4.30%, and 15.10% over the next financial year. EPS should grow at an annualized rate of 7.27% over the next five years, compared to -23.74% over the past 5-year period.
Looking at the support for the AMRX, a number of firms have released research notes about the stock. JP Morgan stated their Neutral rating for the stock in a research note on September 06, 2024, with the firm’s price target at $9. RBC Capital Mkts coverage for the Amneal Pharmaceuticals Inc (AMRX) stock in a research note released on April 07, 2021 offered a Sector Perform rating with a price target of $5. Goldman was of a view on March 08, 2021 that the stock is Buy, while Guggenheim gave the stock Buy rating on December 14, 2020, issuing a price target of $5.50. Barclays on their part issued Overweight rating on December 14, 2020.
